Allergan recently unveiled new data from a multicenter, randomised, double-blind trial that showed 20 Units of VISTABEL® was as effective as 30 Units of Bocouture® for the treatment of moderate to severe glabellar lines. The study results were presented during the 7th European Masters in Anti-Ageing Medicine (EMAA) congress in Paris. “This new study underlines why it is important that medical aesthetic practitioners are aware of the differences between each of the botulinum toxins when selecting the most appropriate treatment for their patients,” comments Dr Moers-Carpi from Munich, Germany and lead investigator for the study. “With botulinum toxin manufacturers each having unique definitions of a unit, aesthetic practitioners should be vigilant in adopting the treatment protocol set by the respective manufacturer and not translating previous experience with one toxin to another.”
A study published in Dermatologic Surgery has indicated that long-pulsed alexandrite laser with a fractional handpiece can produce moderately effective results in treating women with melasma.
Research published in the British Journal of Dermatology has suggested that sunscreen application with a high ultraviolet (UV) index can still allow for vitamin D synthesis, without the risk of sunburn.
Hyaluronic acid product developer IBSA Italia and energy-based medical and aesthetic manufacturer Alma have announced an agreement of strategic partnership.
Research by skin-checking app Miiskin and The British Skin Foundation has revealed that nearly a quarter of Brits have never checked their skin for life-threatening changes, despite a surge in skin cancer deaths over the last decade.
Bio-identical hormone specialist, Dr Marion Gluck, has announced new 2018 dates for the Bio-identical Hormone Replacement Therapy (BHRT) course.
More than 160 European professionals in plastic and oncoplastic surgery met in Paris to discuss new data on a single-use negative pressure wound therapy device (PICO), in the prevention of incisional complications following breast surgery.
Aesthetic product supplier CACI International has released new statistics following a clinical study that took place on 25 female participants trialing the new Simultaneous Photo Electrical Delivery (S.P.E.D) technology.
A study published in the British Journal of Dermatology has suggested that 34% of eczema smartphone apps contain information that is inconsistent with international guidelines, particularly relating to treatments and progression of the condition.
Global pharmaceutical company Allergan has confirmed that it has received Food and Drug Administration (FDA) approval to market JUVÉDERM VOLLURE XC for the correction of moderate to severe facial wrinkles and folds in the US.